Nautilus Biotechnology Reports Third Quarter 2023 Financial Results
Nautilus Biotechnology Reports Third Quarter 2023 Financial Results
SEATTLE, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or "Nautilus"), a company pioneering a single molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2023.
西雅圖,2023年10月31日(環球網)--領先的單分子蛋白質組分析平臺公司鸚鵡螺生物技術公司(納斯達克:NAUT;或“Nautilus”)今天公佈了截至2023年9月30日的第三季度財務業績。
"I'm very pleased with the progress Nautilus made in Q3 as we continue our drive towards commercial readiness", said Sujal Patel, CEO of Nautilus. "Continuing to increase the scale and robustness of the platform remains a key area of focus as we ready the platform for launch next year. With an increasing focus on proteomics by the scientific community, moves by major life science companies to expand their proteomics-related offerings, and massive international investments in the study of proteins, it is clear to me that a strong foundation has been laid for the 'proteomics era' of biology and medicine to take root and flourish. I believe that our continued exceptional financial discipline and business execution, combined with a platform designed to establish a new gold standard for proteomic analysis, positions us well for both short-term and longer-term success."
“我對Nautilus在第三季度取得的進展感到非常高興,因為我們繼續推動商業準備,”Nautilus首席執行官Sujal Patel說。隨著我們為明年推出該平臺做準備,繼續增加該平臺的規模和穩定性仍然是一個關鍵的重點領域。隨著科學界對蛋白質組學的日益關注,各大生命科學公司擴大其蛋白質組學相關產品的舉措,以及對蛋白質研究的大規模國際投資,我清楚地看到,生物學和醫學的“蛋白質組學時代”已經為其紮根和蓬勃發展奠定了堅實的基礎。我相信,我們持續出眾的財務紀律和業務執行,再加上一個旨在建立蛋白質組分析新黃金標準的平臺,使我們為短期和長期的成功奠定了良好的基礎。“
Third Quarter 2023 Financial Results
第三季度2023年年財務業績
Operating expenses were $19.1 million for the third quarter of 2023, a 21% increase from $15.8 million for the three months ended September 30, 2022. The increase in operating expenses was driven primarily by an increase in headcount to support ongoing development of our products.
2023年第三季度的運營費用為1910萬美元,比截至2022年9月30日的三個月的1580萬美元增長了21%。運營費用的增加主要是由於為支持我們產品的持續開發而增加的員工人數。
Net loss was $15.9 million for the third quarter of 2023, as compared to a net loss of $14.1 million for the corresponding prior year period.
2023年第三季度淨虧損為1,590萬美元,而上年同期淨虧損為1,410萬美元。
Cash, cash equivalents, and investments were $275.7 million as of September 30, 2023.
截至2023年9月30日,現金、現金等價物和投資為2.757億美元。
Webcast and Conference Call Information
網路廣播和電話會議資訊
Nautilus will host a conference call to discuss the third quarter 2023 financial results, business developments and outlook before market open on Wednesday, October 31, 2023 at 5:30 AM Pacific Time / 8:30 AM Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio.
Nautilus將在2023年10月31日(星期三)太平洋時間上午5:30/東部時間上午8:30市場開盤前主持電話會議,討論2023年第三季度的財務業績、業務發展和前景。網路直播的現場音頻將在該公司網站的“投資者”欄目中播放,網址為:Www.nautilus.bio。
About Nautilus Biotechnology, Inc.
鸚鵡螺生物技術公司簡介
With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus' mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio
Nautilus公司總部設在華盛頓州西雅圖,研發總部設在加利福尼亞州聖卡洛斯,是一家處於發展階段的生命科學公司,致力於創建一種量化和解鎖蛋白質組複雜性的平臺技術。Nautilus的使命是通過使獲得蛋白質組的途徑民主化並使人類健康和醫學取得根本性進展來改變蛋白質組學領域。欲瞭解更多有關鸚鵡螺的資訊,請訪問www.nautilus.bio。
Special Note Regarding Forward-Looking Statements
關於前瞻性陳述的特別說明
This press release contains forward-looking statements within the meaning of federal securities laws. Forward-looking statements in this press release include, but are not limited to, statements regarding Nautilus' expectations regarding the company's business operations, financial performance and results of operations; expectations with respect to any revenue timing or projections, expectations with respect to the timing of the launch of Nautilus' product platform and full commercial availability, the functionality and performance of Nautilus' product platform, its potential impact on providing proteome access, pharmaceutical development and drug discovery, expanding research horizons, and enabling scientific explorations and discovery, and the present and future capabilities and limitations of emerging proteomics technologies. These statements are based on numerous assumptions concerning the development of Nautilus' products, target markets, and other current and emerging proteomics technologies, and involve substantial risks, uncertainties and other factors that may cause actual results to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that could materially affect the accuracy of Nautilus' assumptions and its ability to achieve the forward-looking statements set forth in this press release include (without limitation) the following: Nautilus' product platform is not yet commercially available and remains subject to significant scientific and technical development, which is inherently challenging and difficult to predict, particularly with respect to highly novel and complex products such as those being developed by Nautilus. Even if our development efforts are successful, our product platform will require substantial validation of its functionality and utility in life science research. In the course of Nautilus' scientific and technical development and associated product validation and commercialization, we may experience material delays as a result of unanticipated events. We cannot provide any guarantee or assurance with respect to the outcome of our development, collaboration, and commercialization initiatives or with respect to their associated timelines. For a more detailed description of additional risks and uncertainties facing Nautilus and its development efforts, investors should refer to the information under the caption "Risk Factors" in our Annual Report on Form 10-K as well as in our Quarterly Report on Form 10-Q to be filed for the quarter ended September 30, 2023 and our other filings with the SEC. The forward-looking statements in this press release are as of the date of this press release. Except as otherwise required by applicable law, Nautilus disclaims any duty to update any forward-looking statements. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
本新聞稿包含符合聯盟證券法的前瞻性陳述。本新聞稿中的前瞻性陳述包括但不限於有關Nautilus對公司業務運營、財務業績和經營結果的預期;對任何收入時間或預測的預期;對推出Nautilus產品平臺和完全商業可用性的時間的預期;Nautilus產品平臺的功能和性能;其在提供蛋白質組訪問、藥物開發和藥物發現、擴大研究視野和實現科學探索和發現方面的潛在影響;以及新興蛋白質組學技術的當前和未來能力和限制。這些陳述基於對Nautilus產品、目標市場以及其他當前和新興蛋白質組學技術的發展的大量假設,涉及大量風險、不確定性和其他因素,可能會導致實際結果與這些前瞻性陳述中明示或暗示的資訊大不相同。可能對Nautilus假設的準確性及其實現本新聞稿中陳述的前瞻性陳述的能力產生重大影響的風險和不確定性包括(但不限於)以下內容:Nautilus的產品平臺尚未投入商業使用,仍在進行重大的科學和技術開發,這本身就具有挑戰性,難以預測,特別是對於像Nautilus正在開發的那些高度新穎和複雜的產品。即使我們的開發努力是成功的,我們的產品平臺也需要對其在生命科學研究中的功能性和實用性進行實質性的驗證。在Nautilus的科學和技術開發以及相關產品驗證和商業化的過程中,我們可能會遇到因意外事件而導致的重大延誤。我們不能就我們的開發、合作和商業化計劃的結果或與其相關的時間表提供任何保證或保證。有關鸚鵡螺及其發展努力面臨的其他風險和不確定性的更詳細描述,投資者應參考我們的年度報告中“風險因素”標題下的資訊,以及我們將提交給美國證券交易委員會的截至2023年9月30日的季度報告和其他報告中的資訊。本新聞稿中的前瞻性陳述是截至本新聞稿發佈之日的。除非適用法律另有要求,否則Nautilus不承擔更新任何前瞻性陳述的責任。因此,您不應依賴這些前瞻性陳述作為我們截至本新聞稿發佈日期之後的任何日期的觀點。
Disclosure Information
披露資訊
Nautilus uses filings with the Securities and Exchange Commission, its website (www.nautilus.bio), press releases, public conference calls, public webcasts, and its social media accounts as means of disclosing material non-public information and for complying with Regulation FD. Therefore, Nautilus encourages investors, the media, and others interested in Nautilus to review the information it makes public in these locations, as such information could be deemed to be material information.
Nautilus使用提交給美國證券交易委員會的檔案、其網站(www.nautilus.bio)、新聞稿、公開電話會議、公共網路廣播和其社交媒體賬戶作為披露重大非公開資訊和遵守FD法規的手段。因此,Nautilus鼓勵投資者、媒體和其他對Nautilus感興趣的人審查它在這些地點公佈的資訊,因為這些資訊可能被視為重要資訊。
Media Contact
press@nautilus.bio
媒體聯繫人
郵箱:Press@nautilus.bio
Investor Contact
investorrelations@nautilus.bio
投資者聯繫方式
郵箱:Investorrelationsnautilus.bio
Nautilus Biotechnology, Inc.
Condensed Consolidated Balance Sheets
As of September 30, 2023 and December 31, 2022 (Unaudited)
鸚鵡螺生物技術公司
簡明綜合資產負債表
截至2023年9月30日和2022年12月31日(未經審計)
(in thousands, except share and per share amounts) |
September 30, 2023 |
December 31, 2022 |
|||||
Assets | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 74,104 | $ | 114,523 | |||
Short-term investments | 109,185 | 69,948 | |||||
Prepaid expenses and other current assets | 3,499 | 2,738 | |||||
Total current assets | 186,788 | 187,209 | |||||
Property and equipment, net | 4,283 | 3,700 | |||||
Operating lease right-of-use assets | 33,669 | 28,866 | |||||
Long-term investments | 92,439 | 129,169 | |||||
Other long-term assets | 1,157 | 1,108 | |||||
Total assets | $ | 318,336 | $ | 350,052 | |||
Liabilities and Stockholders' Equity | |||||||
Current liabilities: | |||||||
Accounts payable | $ | 1,142 | $ | 1,272 | |||
Accrued expenses and other liabilities | 4,285 | 3,528 | |||||
Current portion of operating lease liability | 3,467 | 1,991 | |||||
Total current liabilities | 8,894 | 6,791 | |||||
Operating lease liability, net of current portion | 32,169 | 28,337 | |||||
Total liabilities | 41,063 | 35,128 | |||||
Stockholders' equity: | |||||||
Preferred stock | — | — | |||||
Common stock | 12 | 12 | |||||
Additional paid-in capital | 464,509 | 455,330 | |||||
Accumulated other comprehensive loss | (2,033 | ) | (1,854 | ) | |||
Accumulated deficit | (185,215 | ) | (138,564 | ) | |||
Total stockholders' equity | 277,273 | 314,924 | |||||
Total liabilities and stockholders' equity | $ | 318,336 | $ | 350,052 |
(單位為千,不包括每股和每股金額) |
9月30日, 2023年年 |
十二月三十一日, 2022 |
|||||
資產 | |||||||
流動資產: | |||||||
現金和現金等價物 | $ | 74,104 | $ | 114,523 | |||
短期投資 | 109,185 | 69,948 | |||||
預付費用和其他流動資產 | 3499 | 2738 | |||||
流動資產總額 | 186,788 | 187,209 | |||||
財產和設備,淨額 | 4,283 | 3700 | |||||
經營性租賃使用權資產 | 33,669 | 28,866 | |||||
長期投資 | 92,439 | 129,169 | |||||
其他長期資產 | 1,157 | 1108 | |||||
總資產 | $ | 318,336 | $ | 350,052 | |||
負債與股東權益 | |||||||
流動負債: | |||||||
應付帳款 | $ | 1142 | $ | 1,272 | |||
應計費用和其他負債 | 4,285 | 3528 | |||||
經營租賃負債的當期部分 | 3467 | 1991 | |||||
流動負債總額 | 8894 | 6791 | |||||
經營租賃負債,扣除當期部分 | 32,169 | 28,337 | |||||
總負債 | 41,063 | 35,128 | |||||
股東權益: | |||||||
優先股 | - | - | |||||
普通股 | 12 | 12 | |||||
額外實收資本 | 464,509 | 455,330 | |||||
累計其他綜合損失 | (2,033 | ) | (1,854 | ) | |||
累計赤字 | (185,215 | ) | (138,564 | ) | |||
股東權益總額 | 277,273 | 314,924 | |||||
總負債和股東權益 | $ | 318,336 | $ | 350,052 |
Nautilus Biotechnology, Inc.
Condensed Consolidated Statements of Operations
Three and Nine Months Ended September 30, 2023 and 2022 (Unaudited)
鸚鵡螺生物技術公司
簡明綜合業務報表
截至2023年9月30日和2022年9月30日的三個月和九個月(未經審計)
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
(in thousands, except share and per share amounts) | 2023 | 2022 | 2023 | 2022 | |||||||||||
Operating expenses | |||||||||||||||
Research and development | $ | 11,996 | $ | 9,571 | $ | 34,785 | $ | 28,085 | |||||||
General and administrative | 7,079 | 6,249 | 21,366 | 19,229 | |||||||||||
Total operating expenses | 19,075 | 15,820 | 56,151 | 47,314 | |||||||||||
Other income (expense), net | 3,197 | 1,757 | 9,500 | 2,799 | |||||||||||
Net loss | $ | (15,878 | ) | $ | (14,063 | ) | $ | (46,651 | ) | $ | (44,515 | ) | |||
Net loss per share attributable to common stockholders, basic and diluted | $ | (0.13 | ) | $ | (0.11 | ) | $ | (0.37 | ) | $ | (0.36 | ) | |||
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted | 124,933,837 | 124,651,318 | 124,896,975 | 124,522,164 |
截至9月30日的三個月, | 截至9月30日的9個月, | ||||||||||||||
(單位為千,不包括每股和每股金額) | 2023年年 | 2022 | 2023年年 | 2022 | |||||||||||
運營費用 | |||||||||||||||
研發 | $ | 11,996 | $ | 9571 | $ | 34,785 | $ | 28,085 | |||||||
一般和行政 | 7079 | 6249 | 21,366 | 19,229 | |||||||||||
總運營費用 | 19,075 | 15,820 | 56,151 | 47,314 | |||||||||||
其他收入(費用),淨額 | 3,197 | 1,757 | 9,500 | 2799 | |||||||||||
淨虧損 | $ | (15,878 | ) | $ | (14,063 | ) | $ | (46,651 | ) | $ | (44,515 | ) | |||
普通股股東應佔每股基本虧損和稀釋後每股淨虧損 | $ | (0.13 | ) | $ | (0.11) | ) | $ | (0.37 | ) | $ | (0.36 | ) | |||
加權平均股數,用於計算普通股股東應佔每股淨虧損,包括基本虧損和稀釋虧損 | 124,933,837 | 124,651,318 | 124,896,975 | 124,522,164 |
Nautilus Biotechnology, Inc.
Condensed Consolidated Statements of Cash Flows
Nine Months Ended September 30, 2023 and 2022 (Unaudited)
鸚鵡螺生物技術公司
現金流量表簡明合併報表
截至2023年9月30日和2022年9月30日的9個月(未經審計)
Nine Months Ended September 30, | |||||||
(in thousands) | 2023 | 2022 | |||||
Cash flows from operating activities | |||||||
Net loss | $ | (46,651 | ) | $ | (44,515 | ) | |
Adjustments to reconcile net loss to net cash used in operating activities | |||||||
Depreciation | 1,294 | 871 | |||||
Stock-based compensation | 9,064 | 7,547 | |||||
Amortization (accretion) of premium (discount) on securities, net | (2,040 | ) | (340 | ) | |||
Amortization of operating lease right-of-use assets | 2,821 | 1,624 | |||||
Changes in operating assets and liabilities: | |||||||
Prepaid expenses and other assets | (878 | ) | 239 | ||||
Accounts payable | 22 | (850 | ) | ||||
Accrued expenses and other liabilities | 757 | 860 | |||||
Operating lease liabilities | (2,200 | ) | (865 | ) | |||
Net cash used in operating activities | (37,811 | ) | (35,429 | ) | |||
Cash flows from investing activities | |||||||
Proceeds from maturities of securities | 51,249 | 142,075 | |||||
Purchases of securities | (51,895 | ) | (101,665 | ) | |||
Purchases of property and equipment | (2,029 | ) | (2,095 | ) | |||
Net cash (used in) provided by investing activities | (2,675 | ) | 38,315 | ||||
Cash flows from financing activities | |||||||
Proceeds from exercise of stock options | 23 | 274 | |||||
Proceeds from issuance of common stock under employee stock purchase plan | 92 | 153 | |||||
Net cash provided by financing activities | 115 | 427 | |||||
Net (decrease) increase in cash, cash equivalents and restricted cash | (40,371 | ) | 3,313 | ||||
Cash, cash equivalents and restricted cash at beginning of period | 115,477 | 186,461 | |||||
Cash, cash equivalents and restricted cash at end of period | $ | 75,106 | $ | 189,774 |
截至9月30日的9個月, | |||||||
(單位:千) | 2023年年 | 2022 | |||||
經營活動的現金流 | |||||||
淨虧損 | $ | (46,651 | ) | $ | (44,515 | ) | |
對淨虧損與經營活動中使用的現金淨額進行的調整 | |||||||
折舊 | 1,294 | 871 | |||||
基於股票的薪酬 | 9,064 | 7547 | |||||
證券溢價(折價)攤銷(遞增)淨額 | (2,040 | ) | (340) | ) | |||
經營性租賃使用權資產攤銷 | 2821 | 1,624 | |||||
經營性資產和負債變動情況: | |||||||
預付費用和其他資產 | (878) | ) | 二百三十九 | ||||
應付帳款 | 22 | (850) | ) | ||||
應計費用和其他負債 | 七百五十七 | 八百六十 | |||||
經營租賃負債 | (2,200 | ) | (865) | ) | |||
用於經營活動的現金淨額 | (37,811 | ) | (35,429 | ) | |||
投資活動產生的現金流 | |||||||
證券到期日收益 | 51,249 | 142,075 | |||||
購買證券 | (51,895) | ) | (101,665 | ) | |||
購置財產和設備 | (2,029 | ) | (2,095 | ) | |||
投資活動提供的現金淨額(用於) | (2,675 | ) | 38,315 | ||||
融資活動產生的現金流 | |||||||
行使股票期權所得收益 | 23個 | 二百七十四 | |||||
根據員工購股計劃發行普通股所得款項 | 92 | 153 | |||||
融資活動提供的現金淨額 | 一百一十五 | 427 | |||||
現金、現金等價物和限制性現金淨(減)增 | (40,371 | ) | 3313 | ||||
期初現金、現金等價物和限制性現金 | 115,477 | 186,461 | |||||
期末現金、現金等價物和限制性現金 | $ | 75,106 | $ | 189,774 |